Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RVPH |
---|---|---|
09:32 ET | 2779 | 0.9661 |
09:33 ET | 100 | 0.9821 |
09:35 ET | 196 | 0.9879 |
09:37 ET | 900 | 0.985049 |
09:39 ET | 1350 | 0.983 |
09:46 ET | 2152 | 1.01 |
09:50 ET | 1351 | 1.02 |
09:51 ET | 980 | 1.0174 |
09:53 ET | 4682 | 1.03 |
09:55 ET | 100 | 1.04 |
10:02 ET | 100 | 1.03 |
10:11 ET | 100 | 1.03 |
10:13 ET | 3500 | 1.022593 |
10:15 ET | 100 | 1.02 |
10:27 ET | 2657 | 1.015 |
10:29 ET | 400 | 1.015 |
10:31 ET | 2100 | 1.024 |
10:36 ET | 716 | 1.035 |
10:38 ET | 155 | 1.0347 |
10:44 ET | 100 | 1.035 |
10:45 ET | 5280 | 1.0301 |
10:47 ET | 6335 | 1.0404 |
10:49 ET | 797 | 1.05 |
10:51 ET | 100 | 1.07 |
10:54 ET | 124 | 1.06 |
10:56 ET | 2000 | 1.06 |
10:58 ET | 100 | 1.07 |
11:00 ET | 200 | 1.06 |
11:02 ET | 1000 | 1.06 |
11:03 ET | 2200 | 1.05 |
11:05 ET | 300 | 1.0411 |
11:07 ET | 1900 | 1.04 |
11:12 ET | 200 | 1.045 |
11:14 ET | 100 | 1.0412 |
11:16 ET | 300 | 1.0411 |
11:18 ET | 926 | 1.06 |
11:20 ET | 100 | 1.06 |
11:23 ET | 1000 | 1.0599 |
11:27 ET | 10094 | 1.055 |
11:30 ET | 1000 | 1.055 |
11:32 ET | 217 | 1.0699 |
11:36 ET | 126 | 1.065 |
11:38 ET | 206 | 1.065 |
11:39 ET | 300 | 1.065 |
11:41 ET | 400 | 1.07 |
11:43 ET | 300 | 1.0609 |
11:50 ET | 1600 | 1.0513 |
11:54 ET | 610 | 1.0513 |
11:57 ET | 100 | 1.05 |
12:08 ET | 222 | 1.05 |
12:19 ET | 953 | 1.044 |
12:21 ET | 2700 | 1.045 |
01:09 ET | 15075 | 1.01 |
01:11 ET | 947 | 1.02 |
01:15 ET | 1809 | 1.02 |
01:18 ET | 3700 | 1.02 |
01:20 ET | 1774 | 1.01 |
01:22 ET | 4427 | 1.01 |
01:24 ET | 10082 | 1 |
01:26 ET | 6570 | 1.0001 |
01:27 ET | 100 | 1 |
01:29 ET | 450 | 1.005 |
01:33 ET | 100 | 1.005 |
01:36 ET | 300 | 1 |
01:38 ET | 200 | 1.01 |
01:47 ET | 100 | 1.01 |
01:49 ET | 4802 | 1.0099 |
01:51 ET | 4906 | 1.0045 |
01:54 ET | 1250 | 1.005 |
01:56 ET | 100 | 1.0012 |
01:58 ET | 100 | 1.01 |
02:00 ET | 300 | 1 |
02:02 ET | 2088 | 1.01 |
02:03 ET | 100 | 1.01 |
02:05 ET | 100 | 1.01 |
02:07 ET | 100 | 1.01 |
02:09 ET | 300 | 1.01 |
02:12 ET | 100 | 1.01 |
02:14 ET | 500 | 1.01 |
02:16 ET | 1200 | 1.01 |
02:18 ET | 200 | 1.01 |
02:23 ET | 100 | 1.005 |
02:25 ET | 249 | 1 |
02:27 ET | 6975 | 1.0001 |
02:30 ET | 9600 | 1.005 |
02:34 ET | 11500 | 1.005 |
02:38 ET | 100 | 1.01 |
02:45 ET | 200 | 1.005 |
02:54 ET | 100 | 1.005 |
02:56 ET | 100 | 1.0061 |
02:57 ET | 100 | 1.0077 |
02:59 ET | 198 | 1.0083 |
03:01 ET | 100 | 1.005 |
03:06 ET | 477 | 1.001 |
03:12 ET | 138 | 1 |
03:14 ET | 100 | 1.005 |
03:21 ET | 13093 | 1 |
03:26 ET | 200 | 1.005 |
03:37 ET | 200 | 1.005 |
03:42 ET | 239 | 1.0074 |
03:44 ET | 270 | 1.005 |
03:50 ET | 100 | 1.01 |
03:51 ET | 2492 | 1.01 |
03:53 ET | 100 | 1.03 |
03:55 ET | 400 | 1.01 |
03:57 ET | 8939 | 0.9953 |
04:00 ET | 838 | 0.9985 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Reviva Pharmaceuticals Holdings, Inc. | 33.4M | -0.8x | --- |
AN2 Therapeutics Inc | 32.2M | -0.5x | --- |
Aeon Biopharma Inc | 34.7M | -0.1x | --- |
ALT5 Sigma Corp | 31.8M | -0.7x | --- |
Grace Therapeutics, Inc | 31.8M | -2.6x | --- |
Lantern Pharma Inc | 35.3M | -2.0x | --- |
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $33.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 33.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.04 |
EPS | $-1.30 |
Book Value | $0.20 |
P/E Ratio | -0.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.